Nymox Pharmaceutical Corp. (NYMX)

1.67
NASDAQ : Health Technology
Prev Close 1.69
Day Low/High 1.60 / 1.70
52 Wk Low/High 1.25 / 2.93
Avg Volume 142.30K
Exchange NASDAQ
Shares Outstanding 67.68M
Market Cap 117.82M
EPS -0.20
Div & Yield N.A. (N.A)
Nymox Reports 2012 Financial Results

Nymox Reports 2012 Financial Results

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Biotech Stock Mailbag: Amarin or Arena Takeout?

Biotech Stock Mailbag: Amarin or Arena Takeout?

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Biotech Stock Mailbag: Sangamo Biosciences

Biotech Stock Mailbag: Sangamo Biosciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Nymox Reports 2010 Financial Results

Nymox Reports 2010 Financial Results

Biotech Mailbag: BIO CEO Wrap

Biotech Mailbag: BIO CEO Wrap

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Nymox: Another Look at Enlarged-Prostate Drug

Nymox: Another Look at Enlarged-Prostate Drug

Nymox has more data on its enlarged prostate drug as it progresses through phase III studies but lack of transparency is still a big risk.

TheStreet Quant Rating: D (Sell)